Kestra Medical Technologies (KMTS) News Today

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) shares traded lower after the company reported mixed fiscal first-quarter 2027 results. Strong revenue growth and higher full-year guidance were outweighed by a larger-than-expected loss, contributing to investor caution.

• Positive Sentiment: Kestra reported first-quarter revenue of $30.97 million, representing approximately 60% year-over-year growth and exceeding analyst expectations. Management also raised or reaffirmed fiscal 2027 revenue guidance at $141 million, above the $137.1 million consensus estimate. Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
• Positive Sentiment: Management highlighted a path toward mid-70% gross margins over the next several years, while setting a $141 million fiscal 2027 revenue target. These goals support the long-term growth and profitability case, although they are not immediate earnings results. Kestra targets fiscal 2027 revenue and gross margin goals
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and assigned a $32 price target, implying substantial upside from the recently reported trading level. BTIG rating and price target
• Negative Sentiment: Kestra posted a loss of $0.75 per share, worse than the expected $0.61 loss by $0.14. The company’s net margin remained deeply negative at 138.35%, indicating that rapid revenue growth has not yet translated into profitability. Kestra reports first-quarter loss